Adlai Nortye Ltd. (ANL)
Nasdaq: ANL · Pharmaceutical Preparations · North Brunswick, NJ · filing with the SEC since 2022
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.The Form 20-F filed Apr 10, 2026 for the period ended Dec 31, 2025 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Apr 10, 2026 | Apr 30, 2025 | Apr 19, 2024 | · | · |
| Revenue | 5,000 | · | 5,000 | · | 45,726 |
| Research and development | 32,833 | 44,915 | 58,152 | 54,490 | 42,105 |
| General and administrative | 8,261 | 9,953 | 15,289 | 13,039 | 12,450 |
| Operating income | -35,698 | -52,928 | -72,551r | -67,270 | -8,646 |
| Finance costs | 1,531 | 1,944 | 791 | 433 | 1,337 |
| Share of profit of equity-method investments | -3 | -4 | · | · | · |
| Income before income taxes | -35,528 | -51,869 | -109,228r | -58,790 | -56,678 |
| Income tax expense | · | · | 643 | · | · |
| Net income | -35,528 | -51,869 | -109,228r | -58,790 | -56,678 |
| Net income to shareholders | -35,528 | -51,869 | -109,228r | -58,790 | -56,678 |
| Earnings per share, basic | -0.37 | -0.54 | -2.52r | -2.31 | -2.23 |
| Earnings per share, diluted | -0.37 | -0.54 | -2.52r | -2.31 | -2.23 |
| Weighted average shares, basic | 95,923,415 | 95,776,708 | 43,342,068 | 25,440,000 | 25,440,000 |
| Weighted average shares, diluted | 95,923,415 | 95,776,708 | 43,342,068 | 25,440,000 | 25,440,000 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
ifrs-full:RevenueFromContractsWithCustomers
ifrs-full:RevenueResearch and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
ifrs-full:AdministrativeExpense
ifrs-full:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
ifrs-full:ProfitLossFromOperatingActivitiesFinance costs what its borrowing cost
ifrs-full:FinanceCostsShare of profit of equity-method investments its share of companies it partly owns
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodIncome before income taxes profit before tax
ifrs-full:ProfitLossBeforeTaxIncome tax expense tax charged on the period's profit
ifrs-full:IncomeTaxExpenseContinuingOperationsNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossNet income to shareholders the profit or loss that belongs to the company's shareholders
ifrs-full:ProfitLossAttributableToOwnersOfParentEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageSharesWeighted average shares, diluted the average count with every share that could be issued
ifrs-full:AdjustedWeightedAverageShares